Meir Shinitzky, Ph.D

Head of R&D at Neurogenic. He was previously a Biophysics professor in the Department of Biological Chemistry at the Weizmann Institute in Rehovot, Israel and has authored over 200 scientific
publications, mainly on biochemistry and medicine.

Mila Schechtman, M.Sc

Head of laboratory activities at Neurogenic, including: blood processing, ELISA tests, antigen screenings and test optimization. She is an Organic and Biological Chemistry expert.

Michael Deckmann, Ph.D

Head of blood test theories and practices at Neurogenic. He is a graduate of the Weizmann Institute, under the guidance of Professor M. Shinitzky and subsequently joined the research team at Basel,
Switzerland's Roche institute which developed the HIVl blood test.

Jonathan D. Leitersdorf

Jonathan Leitersdorf holds a Master of Architecture from the Architectural Association, School of Architecture, London and Masters of Science and Real Estate Development from Columbia University, New York City.
He is a member of the Board of Governors of Weizmann Institute of Science, Israel.

Leitersdorf resided in Verbier, Switzerland and his offices are in Geneva, Tel-Aviv and New York. He is the Trustee of Laramie Investment Holding, V.I. and the representative of the family that is the principle shareholder of Neurogenic Ltd.

Yossi Avnat

Yossi Avnat is the CEO of the Wolfson Clore Mayer group of companies for more than 20 years. He has B.A. and M.A. degree in economics from the University of Tel–Aviv and has more than 35 years of
experience. He serves as a director in life science companies and as a director in Neurogenic since its foundation.

Chaim Rosenzweig

Chaim Rosenzweig, Advocate, is the legal advisor of the Wolfson Clore Mayer group of companies to which Neurogenic Ltd. belongs and he has been also a director of Neurogenic since its foundation.